Filing Flows › Comparisons › LXRX vs CAPR
Lexicon Pharmaceuticals vs Capricor Therapeutics: LXRX and CAPR compared
Lexicon Pharmaceuticals is the larger company: $11.2M of revenue in its latest quarter (Q3 2026) against $11.1M for Capricor Therapeutics (Q4 2024). Capricor Therapeutics is growing faster (-8% against -21% a year earlier). Capricor Therapeutics is more profitable, with an operating margin of -69.1% against -128.8%.
Where the money goes: LXRX and CAPR
Lexicon Pharmaceuticals (LXRX) · Q3 2026
Lexicon Pharmaceuticals, Q3 2026: revenue $11.2M (-21% year over year), operating margin -128.8%, net loss $14.0M, operating cash flow −$8.1M. The chart follows the revenue to costs, profit and cash.
Capricor Therapeutics (CAPR) · Q4 2024
Capricor Therapeutics, Q4 2024: revenue $11.1M (-8% year over year), operating margin -69.1%, net loss $7.1M, operating cash flow −$14.8M. The chart follows the revenue to costs, profit and cash.
| Lexicon Pharmaceuticals (LXRX) | Capricor Therapeutics (CAPR) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q4 2024 |
| Revenue | $11.2M | $11.1M |
| Revenue growth, Y/Y | -21% | -8% |
| Operating margin | -128.8% | -69.1% |
| Net earnings | −$14.0M | −$7.1M |
| Net margin | -124.5% | -63.9% |
| Operating cash flow | −$8.1M | −$14.8M |
Questions
Which is bigger, Lexicon Pharmaceuticals or Capricor Therapeutics?
Lexicon Pharmaceuticals is the larger company: $11.2M of revenue in its latest quarter (Q3 2026) against $11.1M for Capricor Therapeutics (Q4 2024).
Is Lexicon Pharmaceuticals or Capricor Therapeutics growing faster?
Capricor Therapeutics is growing faster (-8% against -21% a year earlier).
Which is more profitable, Lexicon Pharmaceuticals or Capricor Therapeutics?
Capricor Therapeutics is more profitable, with an operating margin of -69.1% against -128.8%.
More: Lexicon Pharmaceuticals earnings · how Lexicon Pharmaceuticals makes money · Capricor Therapeutics earnings · how Capricor Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-K filed Mar 26, 2025). Fiscal quarters can end on different dates. Not investment advice.